Table 2.
The biological activities of verticine in references.
| Activities | Models | Biological activities | Action mechanism | Ref. |
|---|---|---|---|---|
| Anti-breast cancer | MCF-7 | Inhibit proliferation, reversing multidrug resistance | - | [4, 5] |
| MCF -7/TAM | Inhibit proliferation (at 48 h IC50=191.16 g/mL; at 72 h, IC50=138.10 g/mL), induce apoptosis | Decrease expression of Bcl-2 | [6] | |
| 4T1 | Inhibit proliferation (at 48h, IC50=14.7 μmol/L) | (1) Down-regulate TGF-β, VEGF and MCP-1 secretion, decrease TGF-β and VEGF mRNA expression, regulating its tumor inflammatory microenvironment. (2) Regulate blood viscosity, improve blood flow state, reduce the expression of u-PA, VEGF, PAI-1 protein and the secretion of IL-8, reduce the infiltration of neutrophils, improve TFPI-2 protein expression | [7, 8] | |
|
| ||||
| Anti-human leukemia | HL60, HL-60/ADR, K562 K562/A02 | Inhibit proliferation (IC50=288.27±34.23, 256.52±26.15, 320.80±36.52, 300.06±33.18, μg/mL), reverse multidrug resistance | Increase intracellular drug concentration and inhibit P-gp protein expression | [5, 9] |
| K562 /A02 | Inhibit the cell viability and induce apoptosis, different concentrations of verticine (100, 200, 400 mol/L); the cell viabilities were 0.392±0.040, 0.314±0.022, 0.161±0.033 | Induce the ROS outbreak and increase the GSH content, redox imbalance | [10, 11] | |
| K562 | Inhibit proliferation (IC50=238 mol/L) | |||
|
| ||||
| Anti-lung cancer | A549/DDP | Inhibit proliferation, induce apoptosis, reversing multidrug resistance | Down-regulate expression of LRP and ERCC1 mRNA | [12, 13] |
|
| ||||
| Anti-gastric cancer | SGC-7901 and SGC-7901/VCR | Inhibit proliferation | - | [14] |
|
| ||||
| Anti-inflammatory effect | 4T1 | Regulate inflammatory microenvironment | Control release of inflammatory factors, such as TGF-β, VEGF, MMP-9, and MCP-1, decreasing the expression of TGF-β and VEGF mRNA | [6] |
| Confluent NCI-H292 cells | Remedy for inflammatory pulmonary diseases | Inhibit gene and protein expression of MUC5AC mucin induced by EGF, PMA or TNF-α by directly acting on airway epithelial cells | [15] | |
| LPS-induced RAW264.7 macrophages | Inhibit production of inflammatory cytokines induced by LPS | Block MAPKs and NF-kB signaling pathways | [16] | |
| HMC-1 Cells | Inhibit production of inflammatory cytokines | Regulate the Phosphorylation of NF-κB and MAPKs | [17] | |
| HEK 293 | anti-inflammatory | Inhibit Kv1.3 channels | [18] | |
| Protection against acute lung injury | Mice | Protective effect on acute lung injury | Inhibit expression of TNF-α, IL-2, IL-6 and IL-8 and COX-2, promote the synthesis and release of SP-A, decrease the levels of PGE2 and NO. And, in addition, down-regulate phosphorylation level of MAPKs in the inflammatory response signaling pathway, and reduce NF-κB gene transcriptional intensity | [19–23] |
|
| ||||
| Tracheobronchial Relaxation | Isolated tracheal strips of guinea pigs | Inhibit contraction | M receptor | [24] |
| rat isolated tracheal and bronchial | Inhibit carbachol-induced contraction | Inhibit influx of calcium ions | [25] | |
|
| ||||
| Antitussive effect | Mice | Antitussive effect for ammonium hydroxide induced cough (4 mg/kg) | - | [26] |
| Guinea pig trachea | Antitussive effect for mechanical stimulation induced cough(4 mg/kg) | - | [26] | |
| Cat superior laryngeal nerve | Antitussive effect electrical stimulation induced cough (4 mg/kg) | - | [26] | |
| Mice | Inhibit cough frequency and increase latent period of cough induced by ammonia | - | [27] | |
|
| ||||
| Expectorant effect | Mice's tracheal | Enhance mice's tracheal phenol red output in expectorant evaluation | Increase tracheobronchial mucus secretion and decrease the viscosity of mucus | [27, 28] |
|
| ||||
| Sedative effect | Mice | Reduce spontaneous activity, prolong pentobarbital sleep time and increase sleep rate | - | [29] |
|
| ||||
| Analgesic effect | Mice | Inhibit writhing reaction induced by acetic acid | Block Nav1.7 ion channel (IC50=47.2±3.3 μM) | [17, 26] |
|
| ||||
| Inhibit proliferation of cultured Orbital fibroblast | Thyroid-associated ophthalmopathy (TAO)-patients | Different concentrations (5, 25,50, 75, 100 mg/L) inhibit the proliferation of orbital fibroblasts in vitro in a dose-dependent manner. | - | [30] |
|
| ||||
| Inhibit angiotensin converting enzyme (ACE) activity | Rat plasma | Inhibit ACE I activity in a dose-dependent manner (IC50=312.8 μM) | - | [31] |
|
| ||||
| Inhibit acetylcholine (AChE) inhibitory activity | At 100 μg/mL, inhibition rate was only 25% | - | [32] | |
|
| ||||
| Inhibit hERG potassium channels | HEK293 cell line | Inhibit hERG peak tail currents with IC50 value of 43.7 mM | channel inactivation, Mutation of Y652 to Alanine reduced sensitivity | [33] |